Apr;16 Suppl 2:S doi: /jx. Abstracts of the 20th ECCMID (European Congress of Clinical Microbiology and. 2) (), p. S (P). Google Scholar. 2. C. Seral, Y. Sáenz, S. Algarate, E. Durán, P. Luque, C. Rubio-Calvo, et mial outbreak of methicillin and. EUCAST at ECCMID in Vienna. The EUCAST Workshop on implementation of EUCAST breakpoints in Europe. MIC breakpoints – the reference for routine.
|Published (Last):||6 June 2016|
|PDF File Size:||15.77 Mb|
|ePub File Size:||9.25 Mb|
|Price:||Free* [*Free Regsitration Required]|
19th European Congress of Clinical Microbiology and Infectious Diseases
To view our latest Nabriva Therapeutics press releasesclick here. Data From US Hospitals. Fosfomycin FOS for Injection: Six posters were presented on lefamulin.
Two from the phase 3 clinical development program, LEAP 1 IV to Oral switch study as monotherapy in adult patients with CABP, described the primary outcome measures of the first phase 3 trial as well as the safety and tolerability data. In 3 in vitro studies, presented were the bactericidal activity of lefamulin against S.
One pre-clinical investigation of the distribution of lefamulin in tissue structures of the urogenital tract in rats was presented. Two epidemiologic investigations presented the hospital-level usage of high-risk antibiotics and associated CDI rates and epidemiology of bacteria in patients with culture-positive CABP who received empiric antibiotic therapy and were admitted to acute-care hospitals in the United States.
Correlation of high-risk antibiotic use and hospital-associated C.
A multicentre evaluation of pathogen distribution in culture positive patients admitted with pneumonia in the US. Nabriva presented a total of 9 posters or oral presentations for lefamulin on Pharmacokinetics in fed and fasted healthy subjects, Population Pharmacokinetic analysis in plasma and epithelial lining fluid, Pharmacokinetic-Pharmacodynamic Target Attainment analyses to support the evaluation of intravenous and oral dosing regimens for the treatment of patients with Community-Acquired Bacterial Pneumonia CABPActivity against the key bacteria known eccmic cause CABP including multi-drug resistant strains and STI – M.
One podium presentation is not yet available. In Vitro Activity of Lefamulin against S.
EUCAST: EUCAST at ECCMID
Nabriva presented data suggesting no major CYPmediated drug-drug interactions are expected with BC Phase 1 data demonstrated safety and tolerability of the intravenous BC formulation. Nabriva presented microbiology results of the Phase 2 pleuromutilin BC, indicating low potential for the emergence of resistant staphylococcal and streptococcal isolates in the clinical setting.
Nabriva presented data showing that BC can be used orally and intravenously for the treatment of skin and lung infections caused by MRSA and other bacteria. The antimicrobial spectrum of BC and its efficacy in non-clinical studies of both skin and lung infections, and data showing the favourable pharmacokinetics of the molecule in clinical Phase 1 i. Nabriva presented data on antimicrobial activity and spectrum of investigational pleuromutilins being developed for topical BC and systemic BC use.
In vitro activity of the novel pleuromutilin lefamulin BC and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrheae.
Antimicrob Agents Chemother Sept Potent drugs for resistant bugs — mode of action and resistance. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China.
Antimicrob Agents Chemother Feb ; 61 2: Simultaneous assessment of the pharmacokinetics eccmjd a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.
Population pharmacokinetic analyses for BC using phase 2 data from patients with acute bacterial skin and skin structure infections. Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.
Poster No. P1500 – Maggie Heginbothom ECCMID 2010
Antimicrobial activity of the pleuromutilin antibiotic BC against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in Phase II clinical study of BC, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
Antimicrobial activity of the novel pleuromutilin antibiotic BC against organisms responsible for community-Acquired respiratory tract infections CARTIs. Antimicrobial activity of the eccmid pleuromutilin compound BC tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure Infections. Are pleuromutilin antibiotics finally fit for human use?
A new class for human use. We bring together a deep level of industry experience, scientific expertise, and heartfelt commitment to patients. Our aim is to deliver innovative therapies that can address serious infectious diseases and eccid growing problem of bacterial resistance.
Antimicrob Agents Chemother Jun 20; 60 7: Ecmid Antimicrob Chemother Apr; 71 4: Antimicrob Agents Chemother Jan; 59 1: Antimicrob Agents Chemother Sept; 57 9: Antimicrob Agents Chemother May; 57 5: J Antimicrob Chemother May; 67 5: Antimicrob Agents Chemother Mar; 56 3: Curr Opin Investig Drugs Feb; 11 2: Meet Our Team We bring together a deep level of industry experience, scientific expertise, and heartfelt commitment to patients.
Explore the Nabriva Pipeline Our aim is to deliver innovative therapies ecccmid can address serious infectious diseases and the growing problem of bacterial resistance.